GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

vi The GSK proprietary AS01 adjuvant system contains ... Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019-32. viii Johnson RW et ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

Credit: GSK KUALA LUMPUR, Sept 10 (Bernama) -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of the Herpes Zoster (HZ) vaccine, Shingrix, also known as Recombinant Zoster ...

A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk (from left to right) Dr Alap Gandhi, Country Medical Director of GSK Malaysia and ...

Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...

Derived from the Latin adjuvare (to help or aid), adjuvants enhance antigen-specific vaccine immunogenicity. Added only when ...